Investigation announced for Investors in shares of Talis Biomedical Corporation (NASDAQ: TLIS) – Press Release


An investigation for investors in Talis Biomedical Corporation (NASDAQ: TLIS) shares over potential securities laws violations.

An investigation for investors in Talis Biomedical Corporation (NASDAQ: TLIS) shares over potential securities laws violations.

An investigation was announced over potential securities laws violations by Talis Biomedical Corporation in connection with certain financial statements.

Investors who purchased shares of Talis Biomedical Corporation (NASDAQ: TLIS), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Talis Biomedical Corporation (NASDAQ: TLIS) concerning whether a series of statements by Talis Biomedical Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Menlo Park, CA based Talis Biomedical Corporation operates as a molecular diagnostic company.

On or about February 12, 2021, Talis Biomedical Corporation (NASDAQ: TLIS) sold approximately 13.8 million shares of stock in its initial public stock offering (the “IPO”) at $16 a share, raising nearly $221 million in new capital.

On August 10, 2021, Talis Biomedical Corporation (NASDAQ: TLIS)reported its 2nd quarter financial results. During the earnings call, it was disclosed that “In the near term, our development time lines have been extended by delays in the launching of our COVID-19 test and manufacturing scale.”

Then, on August 30, 2021, Talis announced that its President, CEO, and Director resigned.

Shares of Talis Biomedical Corporation (NASDAQ: TLIS) declined to as low as $7.01 per share on August 19 and 20, 2021.

Those who purchased shares of Talis Biomedical Corporation (NASDAQ: TLIS) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: [email protected]

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.